We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

89 hedge funds and large institutions have $182M invested in 4D Molecular Therapeutics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

21,600% more call options, than puts

Call options by funds: $1.08M | Put options by funds: $5K

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

11% more funds holding

Funds holding: 80 → 89 (+9)

0.82% less ownership

Funds ownership: 81.35% → 80.53% (-0.82%)

54% less capital invested

Capital invested by funds: $395M → $182M (-$214M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
89
Holders Change
+9
Holders Change %
+11.25%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
23
Increased
27
Reduced
23
Closed
12
Calls
$1.08M
Puts
$5K
Net Calls
+$1.08M
Net Calls Change
-$712K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$13.1M
2
DTC
Deep Track Capital
Connecticut
+$6.73M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$2.71M
4
Millennium Management
Millennium Management
New York
+$1.92M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$9.08M
2
ACM
Aquilo Capital Management
California
-$8.69M
3
State Street
State Street
Massachusetts
-$8.33M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.8M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$3.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$932K +$565K +58,105 +77%
Wellington Management Group
27
Wellington Management Group
Massachusetts
$855K – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$682K -$34.2K -3,515 -3%
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$663K +$923K +94,959 New
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$626K +$871K +89,641 New
Swiss National Bank
31
Swiss National Bank
Switzerland
$451K +$73.9K +7,600 +13%
M&T Bank
32
M&T Bank
New York
$356K +$236K +24,236 +90%
TI
33
Trexquant Investment
Connecticut
$354K +$494K +50,780 New
Two Sigma Investments
34
Two Sigma Investments
New York
$321K +$295K +30,295 +193%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$290K +$63.1K +6,488 +18%
HF
36
HRT Financial
New York
$261K +$364K +37,461 New
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$252K +$32.4K +3,337 +10%
OQS
38
Occudo Quantitative Strategies
Florida
$246K +$343K +35,307 New
PWS
39
Peloton Wealth Strategists
Indiana
$214K +$298K +30,614 New
SSA
40
Schonfeld Strategic Advisors
New York
$205K +$285K +29,300 New
Walleye Capital
41
Walleye Capital
New York
$196K +$273K +28,068 New
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$186K -$102K -10,489 -28%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$179K +$250K +25,670 New
CSS
44
Cubist Systematic Strategies
Connecticut
$165K +$229K +23,568 New
JF
45
Jump Financial
Illinois
$157K +$219K +22,500 New
Bank of America
46
Bank of America
North Carolina
$153K -$836K -86,033 -80%
CIC
47
Cornercap Investment Counsel
Georgia
$150K +$209K +21,543 New
E
48
Ergoteles
New York
$144K +$200K +20,600 New
XT
49
XTX Topco
Cayman Islands
$139K +$194K +19,947 New
AA
50
ALPS Advisors
Colorado
$134K +$186K +19,155 New
1
2
3 4 5

FDMT Hedge Fund Activity: Q2 2022 in Review

89 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2022, worth a combined $182M — down 54% from $395M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new FDMT positions and 12 closed out — a net gain of 11 holders — while 27 added to existing stakes and 23 trimmed.

The largest buyer was BVF Inc, adding an estimated $13.1M. The largest seller was Octagon Capital Advisors, cutting an estimated $9.08M.

  • 89 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2022, up from 80 in Q1 2022.
  • Funds reported $182M of 4D Molecular Therapeutics stock for Q2 2022, down 54% quarter-over-quarter.
  • 23 funds opened new 4D Molecular Therapeutics positions in Q2 2022 and 12 closed out, a net change of +11 holders.
  • The largest 4D Molecular Therapeutics buyer in Q2 2022 was BVF Inc, an estimated $13.1M added.
  • The largest 4D Molecular Therapeutics seller in Q2 2022 was Octagon Capital Advisors, an estimated $9.08M sold.

Based on aggregated 13F filings for Q2 2022.